Downer et al. (2011) also demonstrated that PBMCs from MS patients are refractory to poly(I:C) treatment, in terms of IFN-β expression, thus indicating that blood cells from MS patients may show TLR3 tolerance (Downer et al., 2011). Here, TLR3 is linked to myeloid sarcoma.